Adamas Pharmaceuticals (ADMS) Downgraded by ValuEngine

Adamas Pharmaceuticals (NASDAQ:ADMS) was downgraded by stock analysts at ValuEngine from a “buy” rating to a “hold” rating in a report released on Friday.

A number of other equities analysts also recently commented on ADMS. Leerink Swann reaffirmed an “outperform” rating on shares of Adamas Pharmaceuticals in a research note on Friday, October 19th. BidaskClub raised shares of Adamas Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Tuesday, July 17th. Cowen set a $30.00 target price on shares of Adamas Pharmaceuticals and gave the stock a “buy” rating in a research note on Thursday. Zacks Investment Research downgraded shares of Adamas Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Monday, October 8th. Finally, HC Wainwright set a $45.00 price target on shares of Adamas Pharmaceuticals and gave the company a “buy” rating in a research note on Monday, August 6th. Two analysts have rated the stock with a sell rating, two have issued a hold rating and nine have issued a buy rating to the company. The company currently has an average rating of “Buy” and a consensus price target of $42.00.

Shares of ADMS stock opened at $11.89 on Friday. The company has a debt-to-equity ratio of 0.78, a current ratio of 9.92 and a quick ratio of 9.74. Adamas Pharmaceuticals has a 12 month low of $11.70 and a 12 month high of $44.00.

Adamas Pharmaceuticals (NASDAQ:ADMS) last issued its earnings results on Thursday, November 1st. The specialty pharmaceutical company reported ($1.22) EPS for the quarter, topping analysts’ consensus estimates of ($1.34) by $0.12. Adamas Pharmaceuticals had a negative net margin of 617.27% and a negative return on equity of 104.27%. The company had revenue of $10.61 million for the quarter, compared to the consensus estimate of $10.10 million. Sell-side analysts forecast that Adamas Pharmaceuticals will post -5.37 earnings per share for the current fiscal year.

In other news, CFO Alfred G. Merriweather sold 1,665 shares of the business’s stock in a transaction that occurred on Friday, September 21st. The shares were sold at an average price of $19.18, for a total value of $31,934.70. Following the sale, the chief financial officer now directly owns 25,460 shares of the company’s stock, valued at approximately $488,322.80. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 24.60% of the stock is currently owned by insiders.

Several institutional investors have recently added to or reduced their stakes in the company. Point72 Asset Management L.P. raised its stake in shares of Adamas Pharmaceuticals by 11.6% in the 2nd quarter. Point72 Asset Management L.P. now owns 2,272,115 shares of the specialty pharmaceutical company’s stock valued at $58,689,000 after acquiring an additional 235,515 shares during the period. BlackRock Inc. raised its stake in shares of Adamas Pharmaceuticals by 24.3% in the 2nd quarter. BlackRock Inc. now owns 1,846,096 shares of the specialty pharmaceutical company’s stock valued at $47,684,000 after acquiring an additional 361,303 shares during the period. Macquarie Group Ltd. raised its stake in shares of Adamas Pharmaceuticals by 12.5% in the 2nd quarter. Macquarie Group Ltd. now owns 1,310,310 shares of the specialty pharmaceutical company’s stock valued at $33,846,000 after acquiring an additional 145,412 shares during the period. Emerald Advisers Inc. PA raised its stake in shares of Adamas Pharmaceuticals by 3.5% in the 3rd quarter. Emerald Advisers Inc. PA now owns 662,544 shares of the specialty pharmaceutical company’s stock valued at $13,264,000 after acquiring an additional 22,610 shares during the period. Finally, Emerald Mutual Fund Advisers Trust raised its stake in shares of Adamas Pharmaceuticals by 13.9% in the 3rd quarter. Emerald Mutual Fund Advisers Trust now owns 626,741 shares of the specialty pharmaceutical company’s stock valued at $12,547,000 after acquiring an additional 76,387 shares during the period. 95.23% of the stock is currently owned by institutional investors and hedge funds.

About Adamas Pharmaceuticals

Adamas Pharmaceuticals, Inc discovers, develops, and sells therapies for chronic neurologic disorders. The company's approved/commercial product is GOCOVRI, an amantadine therapy for the treatment of levodopa-induced dyskinesia in patients with Parkinson's disease. Its partnered approved/commercial products include Namzaric (memantine hydrochloride extended-release and donepezil hydrochloride) capsules; and Namenda XR (memantine hydrochloride) extended release capsules for the treatment of moderate to severe Alzheimer's disease.

Further Reading: Why do earnings reports matter?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Adamas Pharmaceuticals (NASDAQ:ADMS)

Receive News & Ratings for Adamas Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamas Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply